TY - JOUR
T1 - Structural insights into the inhibition of glycine reuptake
AU - Shahsavar, Azadeh
AU - Stohler, Peter
AU - Bourenkov, Gleb
AU - Zimmermann, Iwan
AU - Siegrist, Martin
AU - Guba, Wolfgang
AU - Pinard, Emmanuel
AU - Sinning, Steffen
AU - Seeger, Markus A.
AU - Schneider, Thomas R.
AU - Dawson, Roger J. P.
AU - Nissen, Poul
PY - 2021/3/25
Y1 - 2021/3/25
N2 - The human glycine transporter 1 (GlyT1) regulates glycine-mediated neuronal excitation and inhibition through the sodium- and chloride-dependent reuptake of glycine1–3. Inhibition of GlyT1 prolongs neurotransmitter signalling, and has long been a key strategy in the development of therapies for a broad range of disorders of the central nervous system, including schizophrenia and cognitive impairments4. Here, using a synthetic single-domain antibody (sybody) and serial synchrotron crystallography, we have determined the structure of GlyT1 in complex with a benzoylpiperazine chemotype inhibitor at 3.4 Å resolution. We find that the inhibitor locks GlyT1 in an inward-open conformation and binds at the intracellular gate of the release pathway, overlapping with the glycine-release site. The inhibitor is likely to reach GlyT1 from the cytoplasmic leaflet of the plasma membrane. Our results define the mechanism of inhibition and enable the rational design of new, clinically efficacious GlyT1 inhibitors.
AB - The human glycine transporter 1 (GlyT1) regulates glycine-mediated neuronal excitation and inhibition through the sodium- and chloride-dependent reuptake of glycine1–3. Inhibition of GlyT1 prolongs neurotransmitter signalling, and has long been a key strategy in the development of therapies for a broad range of disorders of the central nervous system, including schizophrenia and cognitive impairments4. Here, using a synthetic single-domain antibody (sybody) and serial synchrotron crystallography, we have determined the structure of GlyT1 in complex with a benzoylpiperazine chemotype inhibitor at 3.4 Å resolution. We find that the inhibitor locks GlyT1 in an inward-open conformation and binds at the intracellular gate of the release pathway, overlapping with the glycine-release site. The inhibitor is likely to reach GlyT1 from the cytoplasmic leaflet of the plasma membrane. Our results define the mechanism of inhibition and enable the rational design of new, clinically efficacious GlyT1 inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=85102083803&partnerID=8YFLogxK
U2 - 10.1038/s41586-021-03274-z
DO - 10.1038/s41586-021-03274-z
M3 - Journal article
C2 - 33658720
SN - 1476-4687
VL - 591
SP - 677
EP - 681
JO - Nature
JF - Nature
IS - 7851
ER -